Over the past two decades, animal models of respiratory syncytial virus (RSV) infection have been developed using primates, cotton rats, mice, calves, guinea pigs, ferrets, and hamsters. Use of these models has shed light on the mechanisms of vaccine-enhanced disease seen in clinical trials of a formalin-inactivated RSV vaccine and has provided a means for testing efficacy and safety of candidate prophylactic and therapeutic strategies. The development of multiple animal models has coincided with the realization that RSV disease in humans is a multifaceted disease whose clinical manifestations and sequelae depend upon age, genetic makeup, immunologic status, and concurrent disease within subpopulations. There is no single human subpopulation in whom all forms of RSV disease manifest, nor is there a single animal model that duplicates all forms of RSV disease. The choice of an experimental model will be governed by the specific manifestation of disease to be studied.
Respiratory syncytial virus (RSV) has been enigmatic since or 5 days, and transmission probably occurs via fomites rather than aerosols. There is no viremia. its discovery ú40 years ago. Initially isolated from chimpanzees during an epizootic of upper respiratory tract disease [1] , Pulmonary involvement occurs in 25% -40% of initial infec-RSV was subsequently found to be the most important cause tions but is uncommon in subsequent infections, except those of infectious pulmonary disease in human infants. More rein recent bone marrow transplant recipients or elderly patients. cently, RSV has been shown to be a major pathogen in immuVirus may be shed as long as 20 days. There is no evidence nosuppressed and elderly individuals.
of persistent infection in immunocompetent individuals. Pre-RSV is a member of the family Paramyxoviridae, subfamily mature infants or those with cyanotic congenital heart disease Pneumovirinae, and has a nonsegmented negative stranded geor bronchopulmonary dysplasia are especially likely to develop nome of 15,222 nucleotides (strain A2) [2] . The virion consists severe pulmonary infections with RSV. The immune response of a nucleocapsid within a lipid envelope, and the virions are of infected individuals does not appear to be protective for irregular in size and shape. There are two major glycoproteins longer than a few months; whether the temporary protection expressed on the virion surface: the fusion protein and the is due to antibody or to cellular immunity is unclear. attachment protein. A small hydrophobic protein is also exThe development of the first vaccine (employing the same pressed on the virion surface. Two major antigenic groups (A technology -formalin inactivation -as the highly successful and B) have been described; these groups are distinguished Salk vaccine) and subsequent vaccination of human children primarily by dissimilarities in the attachment protein (1% -7% ended with disastrous results when natural RSV infection derelatedness). Other related viruses include bovine RSV, ovine veloped in those children (up to 80% of children were hospital-RSV, caprine RSV, pneumonia virus of mice, and turkey rhinoized, and two children died) [4] . These results have overshadtracheitis virus. RSV is structurally and functionally similar owed efforts to develop an RSV vaccine for three decades and to parainfluenza viruses, although there is little antigenic or still stand as a barrier to licensure. sequence relationship. RSV is much more distantly related to Interpretation of the vaccine trials was severely hampered the family Orthomyxoviridae (influenza virus), which have a by the lack of a small animal model in which vaccine-enhanced segmented genome.
disease could be reproduced and studied experimentally. In the In one prospective study of children [3] , the rate of RSV absence of such a model, the vaccine's sponsors -observing infection was 68.8 cases per 100 children during the first year that the moderate serum antibody responses in the vaccinees of life and 82.6 cases per 100 children during the second year provided no apparent protection -concluded that serum antiof life. By 24 months of age, all of the children had been body to RSV actually enhanced disease rather than protecting infected at least once, and one-half had had two infections. It against it [5] . This hypothesis gained widespread acceptance is estimated that the incubation period for RSV infection is 4 for nearly 15 years until the advent of small animal models, whereupon studies in those models (particularly the cotton rat model) disproved the hypothesis and established the foundation for antibody-based immunoprophylaxis.
The development of models of RSV infection and disease, erogeneity to be expected among outbred animals and the statistical insignificance of data from so limited a number of observawith RSV-neutralizing activity (RSVIg) could prevent pulmotions raise concerns about the scientific validity of these nary infection and attenuate nasal infection [9 -11] , and these experiments. Furthermore, the scarcity of chimpanzees prestudies established the rationale for clinical trials of RSVIg cludes verification of published observations by other laboraprophylaxis with plasma-derived IgG for infants at high-risk tories. [12, 13] . These trials, in turn, led to the licensure of the first Biological considerations also suggest that the utility of the RSV preventive agent, RespiGam (MedImmune, Inc., Gaitherschimpanzee model is limited. Although advocates of the model burg, MD), in 1996.
emphasize the dramatic rhinorrhea accompanying experimental At the same time, results obtained with animal models chalinfection, no studies have documented pulmonary disease follenged prevailing wisdom concerning RSVIg; they provided lowing primary infection [18] . Furthermore, no evidence exists the foundation for dissecting the mechanisms of vaccine-enthat FI RSV vaccine can produce enhanced disease in the chimhanced disease [14] . These mechanisms are complex, involve panzee, thus raising questions about the relevance of the chimmany arms of the immune response, and are not restricted to panzee as a model of vaccine safety. formalin-inactivated (FI) RSV formulations [15] . As it becomes apparent that various types of formulations, in addition to FI Other Primates RSV vaccine, have the potential of stimulating an inappropriate immune response, the issue of vaccine safety becomes increasExperimental RSV infection has been described in the owl ingly important. Although this issue will not be resolved commonkey [25, 26] , rhesus monkey [23], African green monkey pletely until an RSV vaccine has been tested in seronegative
[27], cebus monkey [28] , squirrel monkey [23], bonnet monkey human infants, the decision to proceed to that stage will be [29] , and baboon [30] . Purchase and maintenance costs for all based in large measure upon studies in animal models. Several of these species (in the United States), although considerably pragmatic issues relating to animal modeling in general are lower than those for the chimpanzee, are still high and tend to listed in table 1. We now describe the most significant animal result in the use of statistically insignificant numbers of animodels of RSV infection and disease, emphasizing the relative mals. Unlike chimpanzees, all of these species may be used in strengths and weaknesses of each model without attempting to terminal experimentation, thus allowing more detailed virologisummarize all of the experimental data derived from their use.
cal and histological studies of pulmonary RSV disease. Although these species all are closer genetically to humans Chimpanzee than are rodents, it has yet to be demonstrated that their use provides data of greater or even equal relevance to the underAlthough no other laboratory animal approaches the genetic relatedness of chimpanzees to humans, practical and biological standing, prevention, and treatment of human disease. Lack of / 9c40$$de46 11-07-97 11:17:14 cida UC: CID inbreeding in any of these species limits immunologic studies, agent in 1996. Therapeutic studies in the cotton rat [9, 43] served as the basis for clinical trials of aerosolized [44] and and relative unrelatedness to humans (compared with the chimpanzee) has meant that few human immunologic reagents crossintravenous [45] IgG treatment of hospitalized infants with RSV disease. Although IgG treatment reduced titers of virus, react. None of these species has been shown to develop either clinical or radiological signs of pulmonary RSV disease, and none of these studies showed a significant effect on clinical outcome. Our more recent work examining a combined antivipulmonary infection has been documented (though not wellcharacterized) only in the owl monkey. Owl monkeys and baral/antiinflammatory approach [46] suggests that modulation of lung inflammation, in addition to clearance of virus, will be boons develop mild rhinorrhea, whereas the other species show no signs of nasal disease.
required for rapid reversal of clinical disease; clinical trials are currently being planned to test this approach. The most useful of these species may be the African green monkey because the enhanced pulmonary disease it develops Although there are several inherent advantages of the cotton rat model, there have been factors that have limited its use. subsequent to immunization with FI RSV vaccine [27] is histologically similar to that seen in humans who died after vaccinaDespite the fact that inbred cotton rats are now available commercially (Virion Systems, Rockville, MD), one major factor tion [4] . However, the large number of animals that would be necessary to characterize fully the enhanced disease, the lack still limiting their use is the lack of reagents for characterization and quantitation of immunoglobulins, complement and other of inbreeding, and the scarcity of immunologic reagents suggest that African green monkeys will be, at best, a secondary model plasma proteins, cell surface antigens, and cytokines. Another disadvantage of the cotton rat is that, unlike the mouse, there are of vaccine-enhanced disease and vaccine safety.
no congenic, transgenic, or knockout strains. The availability of such strains of mice and the unlikelihood of similar strains of Cotton Rat cotton rats being developed suggest that RSV studies requiring such resources will continue to be done in the mouse. RSV infection in the cotton rat was first demonstrated by Dreizin and co-workers [6] , who described the kinetics of viral replication and histological changes in the rats' lungs. The Mouse cotton rat remains uniformly susceptible to pulmonary infection through adulthood, thus establishing it as a useful model for Shortly after RSV was discovered, Coates and Chanock [47] examined several species of laboratory animals to deterlong-term studies [7] . In comparison with the mouse, the cotton rat is 100-fold more permissive (per input dose of virus) and mine if any were permissive for pulmonary viral infection. Among the animals were four strains of inbred mice (DBA/2, more responsive immunologically, developing titers of serum antibody that are 10-fold or more higher [8, 31] . In addition BALB/c, AKR, and C3H). None of these mice developed CF antibody, and only one strain (AKR) developed neutralizing to its greater permissiveness, the cotton rat develops vaccineenhanced pulmonary disease that appears to parallel that in antibody; no attempt to recover infectious virus from the lungs was reported. Prince and co-workers [8] found that each of 20 humans and other primates [14] , whereas the mouse does not [32] . The candidate vaccines of Wyeth-Lederle Vaccines and inbred strains, including the four tested in the earlier report, was permissive for RSV infection in the lungs and nose. Levels Pediatrics (Pearl River, NY) [33] , Upjohn (Kalamazoo, MI) [34] , Pasteur Mérieux Connaught (North York, Ontario, Canof viral replication varied by two orders of magnitude from the least permissive (CBA/CaHN) to the most permissive ada) [35] , SmithKline Beecham Biologicals (Rixensart, Belgium) [36] , and Institut De Recherche Pierre Fabre (Boulogne, (DBA/2N) strains, yet even the most permissive strain was about 100-fold less sensitive than the cotton rat [7] . France) [37] have been tested extensively in the cotton rat, and it currently serves as the primary model for the determination
The mouse model has several advantages over all other species, including a vast array of inbred, congenic, transgenic, and of vaccine safety.
Studies in the cotton rat showed that ribavirin (Virazole, knockout strains; an unmatched library of specific reagents allowing identification and quantitation of cell types, immuno-ICN Pharmaceuticals, Costa Mesa, CA) effected a modest reduction in pulmonary virus (about 10-fold), but no histological globulins, cytokines, and other antigens; and relatively low purchase and maintenance costs. Although no prophylactic or data that might have given clues to the drug's ability to reverse the disease process were provided [38] . Subsequent studies in therapeutic formulations have yet been licensed on the basis of studies in mice, many insights into the immunology of RSV our laboratory failed to demonstrate an ameliorating effect on histopathologic changes [39] , and recent clinical studies showdisease have emerged that could not yet have been obtained from other models (for reviews of such studies, see [48, 49] ). ing marginal or undetectable clinical benefit [40 -42] are consistent with the data for the cotton rat. Studies with the cotton Of particular interest are studies describing different cytokine profiles in animals undergoing various types of immunization, rat model also showed that serum neutralizing antibody was highly effective in preventing pulmonary infection [10, 11] .
including that with FI RSV vaccine [50] . However, although such profiles would be of great value in defining the parameters Subsequent clinical trials confirmed this observation [12, 13] and formed the basis of licensure of RSVIg as a preventive of safe vaccines, distinctly different cell types are obtained / 9c40$$de46 11-07-97 11:17:14 cida UC: CID from different inbred strains with use of bronchoalveolar lavage but no attempt to quantitate viral replication in the lungs or nose was reported. Indeed, no systematic description of viral [51] , and such differences (combined with the histological dissimilarity of vaccine-enhanced disease in the mouse and human replication has yet been published. The only study to quantitate infectious virus in the lungs [58] reported a single time point [32] The chief disadvantages of the guinea pig model are its peated infections throughout life, cause epidemic disease clusapparent limited permissiveness for RSV infection, the general tered during winter months, are attenuated by high levels of unavailability of inbred strains, and the scarcity of immunomaternally derived antibody, and cause severe pulmonary dislogic reagents. ease primarily in neonates [53] . The calf model of bovine RSV infection, however, has many of the same practical drawbacks of primate models: the cost of purchasing and maintaining Ferret animals, lack of inbred strains, and lack of specific reagents.
Two characteristics of clinical disease caused by bovine RSV RSV replicates in high titers in the nasal tissues of ferrets of all ages [47] , but the virus replicates in the lungs only of in calves raise concerns about the usefulness of the calf model. First, bovine RSV commonly causes fever, while human RSV infant animals [62] . Although the rapidly decreasing permissiveness of the lung severely limits the utility of ferrets, it does not [54]. It is not known whether this circumstance is due to differences in the viruses or in host responses. Second, provides an intriguing model for the age dependence of severe RSV disease in humans (in whom the severity of primary bacterial (particularly pasteurella and haemophilus [55] ) and mycoplasmal [56] coinfections are common complications of pulmonary disease is inversely proportional to age); nasal disease in humans does not vary with age [63] . Subsequent studies bovine RSV infection, whereas such coinfections with human RSV have rarely been identified.
of RSV infection in ferret lung tissue and monolayer cultures confirmed in vivo findings, thereby suggesting a local, nonimRecent studies have shown that calves immunized with FI bovine RSV vaccine and then challenged intranasally with live munologic mechanism [64] . Despite the fact that the ferret model has disadvantages similar to those of the guinea pig homologous virus develop enhanced pulmonary disease similar to that seen in humans, African green monkeys, and cotton rats and primate models (lack of inbred strains and immunologic reagents), it is the only model in which age-dependent pulmo- [57] . Although a model employing a viral pathogen in its natural host might have an advantage over a human pathogen in nary infection has been described and thus offers a potential tool for dissecting the mechanisms of age-dependent disease an unnatural host, there are several other factors to consider that might dampen enthusiasm for a calf model of human RSV in humans. infection. The limited homologies of amino acids in several RSV and bovine RSV proteins and the greater difficulty in Hamster propagating and titrating bovine RSV in vitro underscore the fact that these viruses, while related, are not identical. It is The only other animal for which quantitative virological likely that the most sound approach to animal modeling would studies have been reported is the Syrian hamster [65] . Although include the human virus in the most permissive experimental RSV replicated in both the lungs and nose, the relative permishost plus a nonhuman but related virus in its natural host.
siveness of the hamster was equivalent to that of the mouse and was Ç100-fold less than that of the cotton rat. No followGuinea Pig up reports have extended the quantitative studies of Wright et al. [65] , and no studies describing RSV infection in hamsters Coates and Chanock [47] reported that RSV infection in the guinea pig caused a moderate neutralizing antibody response, have been published since 1983.
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